1. Phase I dose-escalation study of the pan-PI3 K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors. (October 2022) Authors: Macy, M.; Cash, T.; Pinto, N.; Pressey, J.G.; Szalontay, L.; Furman, W.L.; Bukowinski, A.; Foster, J.H.; Friedman, G.K.; HaDuong, J.; Fox, E.; Weigel, B.J.; Grevel, J.; Huang, F.; Phelps, C.; Childs, B.H.; Chung, J.; Chaturvedi, S.; Schulz, A.; DuBois, S.G. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗